Orisild (Sildenafil)

Sildenafil, the active ingredient in Orisild, is a phosphodiesterase type 5 (PDE5) inhibitor presented as an oral formulation for oral use. It treats erectile dysfunction in adult males and is also indicated for pulmonary arterial hypertension. GNH USA supplies Orisild as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sildenafil acts on the phosphodiesterase type 5 pathway to improve vascular function in specific conditions.

Erectile dysfunction: enhances the ability to achieve and maintain an erection in men with this condition. Pulmonary arterial hypertension: improves exercise capacity and reduces pulmonary vascular resistance in patients with this disease.

Sildenafil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Facial flushing - Indigestion or dyspepsia - Nasal congestion - Visual disturbances such as blurred vision - Back or muscle pain

Serious or Rare Side Effects: - Priapism (prolonged erection lasting more than 4 hours) - Sudden loss of vision (non‑arteritic anterior ischemic optic neuropathy) - Sudden hearing loss or ringing in the ears - Severe hypotension, especially when combined with nitrates - Cardiovascular events such as myocardial infarction or stroke

Before using Orisild, several safety considerations should be reviewed. - Cardiovascular assessment: evaluate for underlying heart disease or recent myocardial infarction. - Nitrate therapy: avoid concurrent use due to risk of severe hypotension. - Alpha‑blocker use: monitor blood pressure closely if combined. - Hepatic or renal impairment: dose adjustment may be required in severe cases. - Alcohol consumption: limit intake as it may enhance hypotensive effects. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Sildenafil can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin, isosorbide dinitrate): may cause life‑threatening hypotension. - Guanylate cyclase stimulators (e.g., riociguat): can lead to excessive vasodilation. - Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole): increase sildenafil plasma levels.

Moderate Interactions (Monitor Closely): - Alpha‑blockers (e.g., tamsulosin): may cause additive blood pressure lowering. - Certain antihypertensives (e.g., beta‑blockers): monitor for enhanced hypotensive effect. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce sildenafil efficacy.